Nuvation Bio Inc. NUVB R2K
Healthcare · Biotechnology · United States
Nuvation Bio Inc., a clinical-stage biopharmaceutical company, focuses on developing product candidates for cancer treatment. The company's lead product candidate is IBTROZI (taletrectinib), a ROS1 inhibitor for the treatment of patients with ROS1+ non-small cell lung cancer. It is also developing Safusidenib, an inhibitor of mutant isocitrate dehydrogenase 1 in phase 3 clinical trials for the maintenance treatment of high-risk or high-grade IDH1-mutant astrocytoma with safusidenib against placebo. The company was founded in 2018 and is headquartered in New York, New York.
READ MORE ›$4.78
+125.47% 1Y
Market & Price
Market Cap
$1.66B
Current Price
$4.78
High / Low (52W)
$9.54 / $1.71
Beta
1.52
Valuation
Stock P/E
-
Industry PE
23.65
Forward P/E
-
PEG Ratio
-
Book Value
$0.92
Price to Book
5.20
P/S
11.64
EV/EBITDA
-9.09
Dividend Yield
-
Profitability & Returns
ROCE
-37.25%
ROE
-39.51%
ROA
-17.02%
Profit Margin
-
Op Margin
4.66%
EPS (Latest Qtr)
$0.01
EPS (TTM)
$-0.43
Balance Sheet & Liquidity
Debt/Equity
0.68
Quick Ratio
7.04
Current Ratio
7.44
Debt
$216.98M
Total Assets
$594.82M
Current Assets
$571.52M
Working Capital
$489.29M
Ownership
Promoter Holding
18.59%
Chg in Prom Hold
-
FII / Inst Holding
64.82%
Chg in FII Hold
-0.02%
Financial Snapshot
Enterprise Value
$1.35B
Total Revenue (TTM)
$143.05M
EBITDA
$-148.21M
Free Cash Flow
$-100.04M
Operating Cash Flow
$-125.73M
Shares Outstanding
347.20M
Gross Margin
90.78%
Payout Ratio
0.00%
Growth (CAGR)
Revenue 5Y
-
Profit 5Y
-32.13%
Revenue (YoY)
2,598.70%
Earnings (YoY)
-
PROS
No notable strengths flagged.
CONS
- Earnings shrank at -32.1% CAGR over 5 years.
- Trading 49.9% below its 52-week high.
- In a downtrend (50-DMA below 200-DMA).
* The pros and cons are auto-generated from financial metrics.
Price Chart
Technical Trend
Computed from daily close history using EMA cross, slope, and RSI signals.
Note: intraday data is not stored locally. “Hourly” uses the most recent 10 daily candles as a short-term proxy.
Fundamental Growth
No fundamental data available for this stock.
Figures from the latest reported periods. CAGR is computed across the displayed window (quarterly CAGR is annualised assuming 4 quarters per year).
Peer comparison
Peer companies in the same sector (Healthcare).
| # | Name | CMP $ | P/E | Mkt Cap | Div Yld % | ROCE % | ROE % | Rev CAGR 5Y % | Profit CAGR 5Y % |
|---|---|---|---|---|---|---|---|---|---|
| 1 | NUVB Nuvation Bio Inc. R2K | 4.78 | - | $1.66B | - | -37.25% | -39.51% | - | -32.13% |
| 2 | LLY Eli Lilly and Company SPX | 1,105.00 | 39.21 | $985.37B | 0.63% | 38.44% | 107.46% | 31.69% | 48.96% |
| 3 | JNJ Johnson & Johnson SPX | 225.33 | 26.11 | $542.42B | 2.38% | 23.13% | 26.42% | 5.60% | 14.32% |
| 4 | UNH UnitedHealth Group Incorporated SPX | 380.31 | 28.66 | $345.38B | 2.32% | 9.60% | 12.18% | 11.35% | -15.69% |
| 5 | MRK Merck & Co., Inc. SPX | 118.72 | 33.44 | $293.22B | 2.86% | 20.66% | 18.94% | 3.12% | 7.93% |
| 6 | TMO Thermo Fisher Scientific Inc. SPX | 492.51 | 27.11 | $183.03B | 0.38% | 9.17% | 13.52% | -0.27% | -1.19% |
| 7 | AMGN Amgen Inc. NDXSPX | 336.79 | 23.42 | $181.77B | 2.99% | 18.02% | 101.32% | 11.77% | 5.58% |
| 8 | GILD Gilead Sciences, Inc. NDXSPX | 134.43 | 18.29 | $166.90B | 2.44% | 22.92% | 43.36% | 2.57% | 22.83% |
| 9 | ISRG Intuitive Surgical, Inc. NDXSPXAI | 424.64 | 51.53 | $150.39B | - | 15.96% | 17.23% | 17.39% | 29.26% |
Ad space
Quarterly Results
Figures in USD.
| Metric | Mar 2020 | Jun 2020 | Sep 2020 | Mar 2021 | Jun 2021 | Sep 2021 | Mar 2022 | Jun 2022 | Sep 2022 | Mar 2023 | Jun 2023 | Sep 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | - | - | - | - | - | - | 0 | 0 | 0 | 1.44M | 727.00K | - | 3.08M | 4.83M | 13.12M | 41.87M | 83.23M |
| Cost of Revenue | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 2.09M | 2.58M | 3.35M | 1.28M | 5.99M |
| Gross Profit | - | - | - | - | - | - | - | - | - | - | 0 | 0 | 0 | 88.00K | -788.00K | - | 990.00K | 2.26M | 9.77M | 40.59M | 77.24M |
| Operating Expenses | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 59.99M | 65.85M | 66.20M | 74.62M | 73.36M |
| Operating Income | -9.22M | -9.02M | -11.55M | -20.48M | -20.43M | -22.79M | -28.19M | -37.87M | -29.34M | -26.52M | -26.13M | -26.34M | -20.20M | -470.38M | -48.10M | - | -59.00M | -63.59M | -56.43M | -34.04M | 3.88M |
| EBITDA | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | -52.87M | -58.23M | -48.72M | -29.38M | 12.64M |
| Interest Expense | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 54.00K | 421.00K | 6.53M | 6.67M | 6.71M |
| Pretax Income | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | -53.24M | -59.01M | -55.79M | -36.59M | 5.40M |
| Tax Provision | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 0 | 0 | 0 | 0 | 0 |
| Net Income | -8.75M | -8.60M | -11.03M | -20.40M | -19.33M | -21.98M | -21.29M | -34.86M | -27.20M | -21.73M | -20.64M | -19.65M | -14.79M | -462.49M | -41.21M | - | -53.24M | -59.01M | -55.79M | -36.59M | 5.40M |
| Diluted EPS | - | - | - | - | -0.09 | -0.11 | -0.10 | -0.16 | -0.12 | -0.10 | -0.09 | -0.09 | -0.07 | -1.89 | -0.15 | - | -0.16 | -0.17 | -0.16 | -0.11 | 0.01 |
| R&D Expense | 7.29M | 7.34M | 8.63M | 15.88M | 14.03M | 17.12M | 20.73M | 28.92M | 21.29M | 18.79M | 18.59M | 18.56M | 12.84M | 29.25M | 27.73M | - | 24.60M | 27.36M | 28.85M | - | 35.05M |
Profit & Loss (Annual)
Figures in USD.
| Metric | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|
| Revenue | - | - | 0 | 0 | 7.87M | 62.90M |
| Cost of Revenue | - | - | - | 0 | 7.08M | 9.30M |
| Gross Profit | - | - | - | 0 | 795.00K | 53.60M |
| Operating Expenses | - | - | 119.73M | 99.82M | 168.35M | 266.67M |
| Operating Income | -43.55M | - | -119.73M | -99.82M | -167.56M | -213.06M |
| EBITDA | - | - | -119.53M | -75.58M | -566.91M | -189.21M |
| Interest Expense | - | - | - | 0 | 341.00K | 13.68M |
| Pretax Income | - | - | -104.20M | -75.80M | -567.94M | -204.63M |
| Tax Provision | - | - | 0 | 0 | 0 | 0 |
| Net Income | -41.66M | - | -104.20M | -75.80M | -567.94M | -204.63M |
| Diluted EPS | - | -0.44 | -0.48 | -0.35 | -2.11 | - |
| R&D Expense | 32.60M | 69.04M | 87.81M | 71.29M | 99.12M | 115.11M |
Compounded Sales Growth
| 5 Years: | - |
| 1 Year: | 2,598.70% |
Compounded Profit Growth
| 5 Years: | -32.13% |
| 1 Year: | - |
Stock Price Performance
| 1 Year: | +125.47% |
| 6 Months: | -39.34% |
| 3 Months: | -19.12% |
| 1 Month: | +10.14% |
Balance Sheet (Annual)
Figures in USD.
| Metric | Dec 2019 | Apr 2020 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|
| Total Assets | - | - | 221.79M | - | 672.14M | 621.48M | 540.63M | 594.82M |
| Current Assets | - | - | - | - | 667.32M | 616.43M | 526.25M | 571.52M |
| Cash & Equivalents | - | 0 | 29.75M | - | 101.10M | 42.65M | 35.72M | 164.09M |
| Inventory | - | - | - | - | - | - | 0 | 11.41M |
| Receivables | - | - | - | - | - | 0 | 12.72M | 16.08M |
| Total Liabilities | - | - | 6.71M | - | 17.07M | 16.36M | 76.84M | 289.11M |
| Current Liabilities | - | - | 6.55M | - | 13.16M | 13.97M | 58.24M | 82.23M |
| Long Term Debt | - | - | - | - | - | - | - | 47.21M |
| Total Debt | - | - | - | - | 4.26M | 4.01M | 8.91M | 57.35M |
| Total Equity | 117.75M | 0 | 215.08M | - | 655.08M | 605.12M | 463.79M | 305.72M |
| Shares Outstanding | - | - | - | - | 218.63M | 219.05M | 337.84M | 346.50M |
Cash Flows (Annual)
Figures in USD.
| Metric | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|
| Operating Cash Flow | -36.53M | - | -96.11M | -68.00M | -130.41M | -173.43M |
| Investing Cash Flow | -70.32M | - | 63.46M | 8.92M | 122.70M | 99.52M |
| Financing Cash Flow | 133.13M | - | 1.33M | 628.00K | 331.00K | 202.53M |
| Capital Expenditure | - | - | -370.00K | -69.00K | -162.00K | -8.35M |
| Free Cash Flow | - | - | -96.48M | -68.07M | -130.57M | -181.78M |
| Net Change in Cash | - | - | -31.32M | -58.45M | -7.38M | 128.63M |
Ratios (Annual)
Figures in %.
| Metric | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|
| Gross Margin % | - | - | - | - | 10.1% | 85.2% |
| Operating Margin % | - | - | - | - | -2,128.2% | -338.7% |
| Net Margin % | - | - | - | - | -7,213.8% | -325.3% |
| ROE % | -19.4% | - | -15.9% | -12.5% | -122.5% | -66.9% |
| ROCE % | -20.2% | - | -18.2% | -16.4% | -34.7% | -41.6% |
Shareholding Pattern
Insiders
18.59%
Institutions
64.82%
Public Float
79.62%
Top Institutional Holders
| # | Holder | % Held | Shares | Value |
|---|---|---|---|---|
| 1 | FMR, LLC | 14.93% | 51.99M | $248.51M |
| 2 | Decheng Capital LLC | 7.45% | 25.95M | $124.06M |
| 3 | Blackrock Inc. | 7.21% | 25.10M | $119.98M |
| 4 | Vanguard Capital Management LLC | 3.34% | 11.63M | $55.57M |
| 5 | Omega Fund Management, Llc | 2.32% | 8.08M | $38.63M |
| 6 | Laurion Capital Management, LP | 2.25% | 7.82M | $37.39M |
| 7 | State Street Corporation | 1.95% | 6.78M | $32.43M |
| 8 | Geode Capital Management, LLC | 1.68% | 5.86M | $28.03M |
| 9 | Duquesne Family Office Llc | 1.30% | 4.54M | $21.70M |
| 10 | Bank of America Corporation | 0.92% | 3.22M | $15.39M |
Analyst View
Loading analyst coverage…
Analyst aggregate. Targets and ratings update periodically; not investment advice.
Latest News
Recent headlines for NUVB
No recent headlines available.